Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Scientists at University of Texas, M. D. Anderson Cancer Center publish research in cancer vaccines
September 23rd, 2008
Scientists discuss in 'The E75 HER2/neu peptide vaccine' new findings in cancer. "E75 (HER2/neu 369-377) is an immunogenic peptide from the HER2/neu protein which is overexpressed in many breast cancer patients. A large amount of preclinical work and a small number of Phase I trials have been completed evaluating the vaccine potential of the E75 peptide mixed with an immunoadjuvant," scientists writing in the journal Cancer Immunology, Immunotherapy report. "Our group has performed two concurrent E75 + GM-CSF Phase II trials in node-positive and node-negative disease-free breast cancer patients. These trials, totaling 186 patients, were designed to assess the...
Source: Cancer Weekly (2008-09-23)
|
